Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.31)
# 2,716
Out of 5,017 analysts
75
Total ratings
51.28%
Success rate
-4.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $1.48 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $26.26 | - | 3 | Sep 9, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $203 | $211.80 | -4.15% | 19 | Aug 8, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $4.49 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $9.77 | - | 11 | Jun 26, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $31.05 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.80 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $5.38 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $9.49 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $1.67 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.95 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.35 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.58 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.13 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $2.00 | +50.00% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.55 | +223.62% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.17 | +1,651.15% | 1 | Aug 12, 2022 |
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $1.48
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $26.26
Upside: -
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $200 → $203
Current: $211.80
Upside: -4.15%
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $4.49
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.77
Upside: -
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $31.05
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.80
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.38
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.49
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.67
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.95
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.35
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.58
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.13
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $2.00
Upside: +50.00%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.55
Upside: +223.62%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.17
Upside: +1,651.15%